{
    "nctId": "NCT00146588",
    "briefTitle": "Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer",
    "officialTitle": "A Pilot Study of Cytoxan, Epirubicin, and Capecitabine in Women With Stage I/II/IIIA Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 55,
    "primaryOutcomeMeasure": "To determine the feasibility of administering cytoxan, epirubicin, and capecitabine to women with Stage I/II/IIIA breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed Stage I-III breast cancer. If Stage I, should be deemed of sufficiently high risk of developing recurrent disease to warrant participation.\n* 18 years of age or older\n* ANC \\> 1,000/mm3\n* Platelet count \\> 100,000/mm3\n* Hemoglobin \\> 10\n* Creatinine \\< 2.0\n* SGOT \\< 2 x ULN\n* Bilirubin \\< 1.5mg/dl\n* Able to swallow and retain oral medication\n* LVEF greater than or equal to 50%\n* ECOG performance status of 0 or 1\n\nExclusion Criteria:\n\n* Pregnant or lactating\n* Prior malignancy within 5 years (excluding squamous or basal cell skin cancers)\n* Prior chemotherapy within 5 years\n* Prior anthracycline therapy\n* Serious comorbid physical or psychological condition",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}